AI Engines For more Details: Perplexity Kagi Labs You
Contraception: Chlormadinone acetate is commonly used as a component of combined oral contraceptives (COCs). It works by inhibiting ovulation (the release of eggs from the ovaries), thickening cervical mucus to prevent sperm penetration, and thinning the uterine lining to prevent implantation.
Menstrual Disorders: Chlormadinone acetate may be prescribed to regulate menstrual cycles and alleviate symptoms of menstrual disorders such as irregular or heavy menstrual bleeding, dysmenorrhea (painful menstruation), and premenstrual syndrome (PMS).
Endometriosis: It is sometimes used in the treatment of endometriosis, a condition in which the tissue that normally lines the inside of the uterus grows outside the uterus, causing pain and other symptoms. Chlormadinone acetate can help suppress the growth of endometrial tissue and reduce associated symptoms.
Hormone Replacement Therapy (HRT): Chlormadinone acetate may be included in hormone replacement therapy regimens for postmenopausal women to alleviate symptoms such as hot flashes, night sweats, vaginal dryness, and mood changes.
Acne: Chlormadinone acetate is sometimes prescribed off-label for the treatment of acne, particularly in women with hormonal acne. It can help reduce sebum production and regulate hormone levels to improve acne symptoms.
Hirsutism: In some cases, chlormadinone acetate may be used to treat hirsutism, a condition characterized by excessive hair growth in women, particularly in areas where men typically grow hair (such as the face, chest, and back). It can help reduce the growth of unwanted hair by inhibiting androgen activity.
Side Effects: Common side effects of chlormadinone acetate may include nausea, breast tenderness, headache, mood changes, weight changes, and changes in menstrual bleeding patterns. These side effects are usually mild and transient but may require medical attention if severe or persistent.
Contraindications: Chlormadinone acetate is contraindicated in individuals with known hypersensitivity to the drug, as well as those with a history of thromboembolic disorders, liver disease, or certain types of cancer (such as breast cancer). It should be used with caution in individuals with a history of cardiovascular disease or other risk factors for thrombosis.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.2 | -0.2 | |
| ADHD | 2.5 | 2.5 | |
| Age-Related Macular Degeneration and Glaucoma | 0 | 0.4 | 0 |
| Allergic Rhinitis (Hay Fever) | 0.8 | 0.6 | 0.33 |
| Allergies | 1.5 | 0.9 | 0.67 |
| Allergy to milk products | 0.5 | 0.6 | -0.2 |
| Alopecia (Hair Loss) | 1 | 1 | |
| Alzheimer's disease | 1.2 | 1.6 | -0.33 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.1 | 0.2 | 4.5 |
| Ankylosing spondylitis | 1.7 | 0.3 | 4.67 |
| Anorexia Nervosa | 0.4 | 0.7 | -0.75 |
| Antiphospholipid syndrome (APS) | 0.3 | 0.3 | |
| Asthma | 0.4 | 0.4 | 0 |
| Atherosclerosis | 0.4 | 0.9 | -1.25 |
| Atrial fibrillation | 1.3 | 0.9 | 0.44 |
| Autism | 4.1 | 3.5 | 0.17 |
| Barrett esophagus cancer | 0.1 | 0.2 | -1 |
| benign prostatic hyperplasia | 0 | 0 | |
| Bipolar Disorder | 0.7 | 0.2 | 2.5 |
| Brain Trauma | 0.3 | 0.3 | 0 |
| Carcinoma | 1.6 | 1.4 | 0.14 |
| Celiac Disease | 1.6 | 1.4 | 0.14 |
| Cerebral Palsy | 0.8 | 0.4 | 1 |
| Chronic Fatigue Syndrome | 2.7 | 3.8 | -0.41 |
| Chronic Kidney Disease | 0.6 | 0.2 | 2 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.7 | 0 | 0 |
| Chronic Urticaria (Hives) | 0.6 | 0.7 | -0.17 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 0.4 | 0.75 |
| Colorectal Cancer | 2.2 | 0.4 | 4.5 |
| Constipation | 1 | 0.2 | 4 |
| Coronary artery disease | 0.3 | 0.2 | 0.5 |
| COVID-19 | 5.1 | 5.8 | -0.14 |
| Crohn's Disease | 3 | 2.1 | 0.43 |
| cystic fibrosis | 0.1 | 0.4 | -3 |
| deep vein thrombosis | 0.1 | 0.3 | -2 |
| Depression | 5.5 | 3.3 | 0.67 |
| Dermatomyositis | 0.2 | 0.2 | 0 |
| Eczema | 0.2 | 1.4 | -6 |
| Endometriosis | 1.2 | 0.5 | 1.4 |
| Eosinophilic Esophagitis | 0 | 0.1 | 0 |
| Epilepsy | 1.4 | 1.9 | -0.36 |
| Fibromyalgia | 1.7 | 1.3 | 0.31 |
| Functional constipation / chronic idiopathic constipation | 3 | 2 | 0.5 |
| gallstone disease (gsd) | 0.9 | 0.2 | 3.5 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.4 | 0.4 | 2.5 |
| Generalized anxiety disorder | 0.2 | 0.6 | -2 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.2 | -0.2 | |
| Graves' disease | 1 | 0.3 | 2.33 |
| Halitosis | 0.4 | 0.2 | 1 |
| Hashimoto's thyroiditis | 0.6 | 0.4 | 0.5 |
| Hidradenitis Suppurativa | 0.2 | 0.1 | 1 |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.1 | 0.1 | 10 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.1 | 4 |
| hyperglycemia | 0 | 1.1 | 0 |
| Hyperlipidemia (High Blood Fats) | 0.4 | 0.2 | 1 |
| hypersomnia | 0.1 | -0.1 | |
| hypertension (High Blood Pressure | 1.3 | 1.8 | -0.38 |
| Hypothyroidism | 0.3 | -0.3 | |
| Hypoxia | 0.7 | 0.7 | |
| IgA nephropathy (IgAN) | 1.7 | -1.7 | |
| Inflammatory Bowel Disease | 1.8 | 2.8 | -0.56 |
| Insomnia | 0.5 | 0.3 | 0.67 |
| Intelligence | 0.8 | 0.1 | 7 |
| Intracranial aneurysms | 0.8 | 0.2 | 3 |
| Irritable Bowel Syndrome | 1.9 | 3 | -0.58 |
| Liver Cirrhosis | 1.9 | 1.1 | 0.73 |
| Long COVID | 3.8 | 2.6 | 0.46 |
| Low bone mineral density | 0 | 0 | |
| Lung Cancer | 0.8 | 0.3 | 1.67 |
| ME/CFS with IBS | 0.7 | 0.6 | 0.17 |
| ME/CFS without IBS | 0.5 | 1.1 | -1.2 |
| Menopause | 0.9 | 0.9 | |
| Metabolic Syndrome | 3.6 | 4.1 | -0.14 |
| Mood Disorders | 6.5 | 3.3 | 0.97 |
| multiple chemical sensitivity [MCS] | 0.7 | 0.1 | 6 |
| Multiple Sclerosis | 1.5 | 2.9 | -0.93 |
| Multiple system atrophy (MSA) | 0.2 | 0.4 | -1 |
| Neuropathy (all types) | 0.3 | 0 | 0 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.8 | 1.6 | -1 |
| NonCeliac Gluten Sensitivity | 0.2 | -0.2 | |
| Obesity | 3.4 | 2.2 | 0.55 |
| obsessive-compulsive disorder | 4.2 | 1 | 3.2 |
| Osteoarthritis | 0.7 | 0.1 | 6 |
| Osteoporosis | 0.6 | 0.4 | 0.5 |
| pancreatic cancer | 0.5 | 0.5 | |
| Parkinson's Disease | 1.1 | 1.1 | 0 |
| Polycystic ovary syndrome | 1.8 | 0.9 | 1 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.2 | 0 |
| Premenstrual dysphoric disorder | 0.5 | 0.4 | 0.25 |
| primary biliary cholangitis | 0.7 | -0.7 | |
| Psoriasis | 1.8 | 1.6 | 0.13 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.9 | 1.7 | 0.12 |
| Rosacea | 0.3 | 0.2 | 0.5 |
| Schizophrenia | 3.2 | 0.6 | 4.33 |
| scoliosis | 0.1 | -0.1 | |
| Sjögren syndrome | 1.5 | 1.9 | -0.27 |
| Sleep Apnea | 0.4 | 0.4 | 0 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
| Stress / posttraumatic stress disorder | 1.2 | 0.7 | 0.71 |
| Systemic Lupus Erythematosus | 1.8 | 0.7 | 1.57 |
| Tic Disorder | 1.1 | 0.5 | 1.2 |
| Tourette syndrome | 0.1 | 0.2 | -1 |
| Type 1 Diabetes | 2.4 | 1.5 | 0.6 |
| Type 2 Diabetes | 4.1 | 3.5 | 0.17 |
| Ulcerative colitis | 1.1 | 3.5 | -2.18 |
| Unhealthy Ageing | 2.6 | 0.6 | 3.33 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.